Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer.

Apoptosis : an international journal on programmed cell death - 20 Aug 2026

Xie Jingyi, Wang Simeng, Liu Juan, Zhang Yan, Zhu Haixiao, Cui Rongrong, Yao Yao, Yu Wei, Hou Peng

Abstract excerpt

KRAS mutations are among the most common genetic alterations in colorectal cancer (CRC) and are strongly linked to poor prognosis and therapeutic resistance. However, current treatments targeting KRAS-mutated CRC have shown limited clinical efficacy. Argonaute 2 (AGO2) is a critical component in microRNA (miRNA)-mediated gene silencing complex, which is involved in the maturation of miRNAs and the regulation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Argonaute Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Fluorouracil

Share to Immunotherapy

Share to MicroRNAs

Share to Peptides

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 42622908
DOI: 10.1007/s10495-026-02429-5

Genes

KRAS
AGO2
ABCC5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer.PMID 42622908Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

Selective targeting of point-mutated KRAS through artificial microRNAs.Semantic proximity Read ↗

Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.Semantic proximity Read ↗

Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.Semantic proximity Read ↗

MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards TherapySemantic proximity Read ↗

Quadruple-editing of MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cellsSemantic proximity Read ↗

KRAS Engages AGO2 to Enhance Cellular Transformation.Semantic proximity Read ↗

An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development.Semantic proximity Read ↗

Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.Semantic proximity Read ↗

KRAS Hijacks the miRNA Regulatory Pathway in Cancer.Semantic proximity Read ↗

Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptidesSemantic proximity Read ↗

Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.